SCIENTIFIC ADVISORY BOARD
Robert L. Martuza - Massachusetts General Hospital
Robert L. Martuza, M.D., is a Distinguished Professor of Neuroscience at the Harvard Medical School, and Chief Emeritus of Neurosurgery Service at the Massachusetts General Hospital. His pioneering work has led multiple other investigators to study other oncolytic viruses for cancer therapy and to the approval of two different oncolytic viruses for clinical use world-wide. Dr. Martuza has published over 200 peer reviewed articles on oncolytic virotherapy, cancer therapy and immunotherapy, and brain neoplasms.
Katy Rezvani - The University of Texas MD Anderson Cancer Center
Katy Rezvani, M.D., Ph.D., is a Professor of Medicine, Director of Translational Research, Medical Director of the MD Anderson GMP and Cell Therapy Laboratory and Chief, Section of Cellular Therapy, Department of Stem Cell Transplant and Cellular Therapy, MD Anderson Cancer Center. Dr. Rezvani leads the NK immunotherapy program at MD Anderson and has translated multiple innovative immunotherapy strategies from bench to bedside.
George R. Blumenschein - The University of Texas MD Anderson Cancer Center
Dr. George R. Blumenschein, Jr. is a Professor of Medicine in the Department of Thoracic/Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. He has authored or co-authored numerous papers and book chapters regarding the management of lung and head and neck cancers. He is leading the Adoptive T-cell Program with the goal of developing this class of therapeutics for the treatment of Lung and Head and Neck Cancers and serves as the principle investigator on multiple clinical trials.
Brad Nelson - BC Cancer Agency
Brad Nelson, Ph.D., is a Distinguished Scientist and founding Director of the Deeley Research Center since 2003, Co-Director of the Immunotherapy Program at BC Cancer Agency, a Professor of Biochemistry/Microbiology at the University of Victoria, and a Professor of Medical Genetics at the University of British Columbia. Dr. Nelson’s lab uses genomic and molecular approaches to study the immune response to cancer, with an emphasis on ovarian cancer. He is leading a phase I clinical trials program focused on adoptive T-cell therapy for gynecological cancers, leukemia, lymphoma, and other malignancies.
Mann Fung - Independent Consultant (Formerly at J&J Innovation)
Dr. Mann Fung was VP Oncology Scientific Innovation at Johnson & Johnson Innovation Centre, Asia Pacific, responsible for creating and implementing an external innovation plan focused on developing an industry-leading portfolio of oncology investment opportunities in Asia Pacific. Previously, Dr. Fung was the Vice President, Compound Development Team Leader at Janssen. He was also the Executive Director/Head of Specialty Pharma Development at McNeil. Prior to joining Johnson & Johnson, Dr. Fung was the Head of Oncology & Critical Care at Eli Lilly Japan and a Team Leader and Reviewer at the FDA.
Li Jin - Vice-President of Fudan University
Dr. Li Jin is a Chinese geneticist, Academician of the Chinese Academy of Sciences, and the Vice-President of Fudan University. He is also a foreign member of Max Planck Society, Director of the Human Genome Organization, and a member of the “Thousand Talents Plan”. Dr. Jin earned his Bachelor’s and Master’s degrees in Genetics from Fudan University, and obtained his PhD in Biomedicine/Genetics from University of Texas Health Science Center. Dr. Jin has published 280 Scientific Citation Index in international publications such as Nature, Science and PNA; and his work has been cited over 14,000 times.